ClinicalTrials.gg

Program

SKB500

A development code. Also written as “SKB500 Powder for Injection”.

Its studies are mostly in Esophageal Squamous Cell Carcinoma · Small Cell Lung Carcinoma, led by Sichuan Kelun Pharmaceutical.

Furthest: phase 2, since Nov 25, 20253 company-led studies, 3 open or runningNext primary completion: Jul 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Kelun Pharmaceutical33 open or runningphase 2since Nov 25, 2025Dec 9, 2024Jul 31, 2027phase 1 · NCT06736327

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2024First study: phase 1 study in Advanced Solid TumorsFirst studyNCT06736327 · 180 planned · China
  2. Nov 25, 2025Phase 2 study in Small Cell Lung CarcinomaPhase 2 reachedNCT07296809 · 80 planned · China
  3. Jul 8, 2026Phase 2 study in Esophageal Squamous Cell CarcinomaNCT07700667 · 120 planned · China

Ahead

  1. Jul 31, 2027Primary completion: phase 1 study in Advanced Solid TumorsNCT06736327
  2. Dec 31, 2028Primary completion: phase 2 study in Esophageal Squamous Cell CarcinomaNCT07700667
  3. Dec 31, 2028Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT07296809

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07700667Esophageal Squamous Cell Carcinoma · China2RecruitingDec 31, 2028120
NCT07296809Small Cell Lung Carcinoma · China2RecruitingDec 31, 202880
NCT06736327Advanced Solid Tumors · China1RecruitingJul 31, 2027180

How it is read

Names in the registry

  • “SKB500”, 2 entries
  • “SKB500 Powder for Injection”, 1 entry

Codes read as this program: SKB500.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.